Tag: Arch Biopartners

March 19, 2019

Arch Biopartners Receives Approval to Perform Phase I Clincial Trial for Metablok in Australia

Arch Biopartners (TSXV:ARCH,OTCQB:ACHFF) has announced it has been granted approval by the Alfred Hospital Ethics Committee to perform a Phase...
October 29, 2018

Arch Biopartners Provides Toxicology Update for Metablok

Arch Biopartners (TSXV:ARCH;OTCQB:ACHFF) today provided an update on the general results from toxicology and pharmacology studies evaluating Metablok, the Company’s...
May 8, 2018

Arch Biopartners Completes Pre-IND Meeting with U.S. FDA on LSALT Peptide for Preventing Acute Kidney Injury in Cardiac Surgery Patients

Arch Biopartners (TSX Venture:ARCH) (OTCBB:ACHFF), announced today it completed a successful pre-IND (Investigational New Drug) meeting via teleconference on April...
March 27, 2018

Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569

Arch Biopartners (TSXV:ARCH) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 9,925,206 protecting the composition and...
February 27, 2018

Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio

Arch Biopartners (TSXV:ARCH) a portfolio-based biotechnology company, today announced CSBio of Menlo Park, California,  has started the good manufacturing practice...
January 26, 2018

Arch Biopartners Announces Non Brokered Private Placement Financing

Arch Biopartners (TSXV:ARCH) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 2,500,000...
September 28, 2017

Arch Biopartners Provides Update on AB569 Progress

Arch Biopartners announced the good manufacturing practice production campaign for AB569 has advanced to the GMP glass vial filling stage.